WO2003096977A3 - Methods of treating hepatitis - Google Patents

Methods of treating hepatitis Download PDF

Info

Publication number
WO2003096977A3
WO2003096977A3 PCT/US2003/015263 US0315263W WO03096977A3 WO 2003096977 A3 WO2003096977 A3 WO 2003096977A3 US 0315263 W US0315263 W US 0315263W WO 03096977 A3 WO03096977 A3 WO 03096977A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating hepatitis
patient
hepatitis
treating
Prior art date
Application number
PCT/US2003/015263
Other languages
French (fr)
Other versions
WO2003096977A2 (en
Inventor
Leo E Otterbein
Augustine M K Choi
Brian Zuckerbraun
Original Assignee
Univ Yale
Univ Pittsburgh
Leo E Otterbein
Augustine M K Choi
Brian Zuckerbraun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03728926A priority Critical patent/EP1505990B1/en
Priority to JP2004504976A priority patent/JP4549847B2/en
Priority to UA20041210382A priority patent/UA83465C2/en
Priority to MXPA04011426A priority patent/MXPA04011426A/en
Application filed by Univ Yale, Univ Pittsburgh, Leo E Otterbein, Augustine M K Choi, Brian Zuckerbraun filed Critical Univ Yale
Priority to AU2003234585A priority patent/AU2003234585B2/en
Priority to EA200401525A priority patent/EA200401525A1/en
Priority to AT03728926T priority patent/ATE521357T1/en
Priority to CN038163233A priority patent/CN1668314B/en
Priority to YUP-993/04A priority patent/RS99304A/en
Priority to DK03728926.1T priority patent/DK1505990T3/en
Priority to CA002485465A priority patent/CA2485465A1/en
Publication of WO2003096977A2 publication Critical patent/WO2003096977A2/en
Publication of WO2003096977A3 publication Critical patent/WO2003096977A3/en
Priority to HR20041071A priority patent/HRP20041071A2/en
Priority to NO20045056A priority patent/NO20045056L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.
PCT/US2003/015263 2002-05-17 2003-05-16 Methods of treating hepatitis WO2003096977A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA200401525A EA200401525A1 (en) 2002-05-17 2003-05-16 METHODS OF TREATMENT OF HEPATITIS (OPTIONS)
UA20041210382A UA83465C2 (en) 2002-05-17 2003-05-16 Method of treating hepatitis with carbon monoxide
MXPA04011426A MXPA04011426A (en) 2002-05-17 2003-05-16 Methods of treating hepatitis.
CN038163233A CN1668314B (en) 2002-05-17 2003-05-16 Methods of treating hepatitis
AU2003234585A AU2003234585B2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis
JP2004504976A JP4549847B2 (en) 2002-05-17 2003-05-16 How to treat hepatitis
AT03728926T ATE521357T1 (en) 2002-05-17 2003-05-16 METHOD FOR TREATING HEPATITIS
EP03728926A EP1505990B1 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis
YUP-993/04A RS99304A (en) 2002-05-17 2003-05-16 Methods of treating hepatitis
DK03728926.1T DK1505990T3 (en) 2002-05-17 2003-05-16 Methods for the treatment of hepatitis
CA002485465A CA2485465A1 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis
HR20041071A HRP20041071A2 (en) 2002-05-17 2004-11-16 Methods of treating hepatitis
NO20045056A NO20045056L (en) 2002-05-17 2004-11-19 Methods for the treatment of hepatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38152702P 2002-05-17 2002-05-17
US60/381,527 2002-05-17

Publications (2)

Publication Number Publication Date
WO2003096977A2 WO2003096977A2 (en) 2003-11-27
WO2003096977A3 true WO2003096977A3 (en) 2004-03-11

Family

ID=29550139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015263 WO2003096977A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Country Status (16)

Country Link
US (4) US20040052866A1 (en)
EP (1) EP1505990B1 (en)
JP (1) JP4549847B2 (en)
CN (1) CN1668314B (en)
AT (1) ATE521357T1 (en)
CA (1) CA2485465A1 (en)
DK (1) DK1505990T3 (en)
EA (1) EA200401525A1 (en)
ES (1) ES2372273T3 (en)
HR (1) HRP20041071A2 (en)
MX (1) MXPA04011426A (en)
NO (1) NO20045056L (en)
PL (1) PL205066B1 (en)
RS (1) RS99304A (en)
UA (1) UA83465C2 (en)
WO (1) WO2003096977A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
SK15942003A3 (en) * 2001-06-21 2004-08-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants apoptosis
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003223562B2 (en) * 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
AU2003216368B2 (en) * 2002-04-15 2007-08-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
US20040052866A1 (en) 2002-05-17 2004-03-18 Otterbein Leo E. Methods of treating hepatitis
CA2487413A1 (en) * 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20040218547A1 (en) 2003-04-30 2004-11-04 Rhodey William George Process modification to maximize benzene production
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073006A1 (en) * 2005-12-22 2007-06-28 Keio University Inducer for increasing of content of cytoprotective amino acid and method for increasing the content
JPWO2007073005A1 (en) * 2005-12-22 2009-06-04 学校法人慶應義塾 Methyl group transfer regulator
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP2012504653A (en) * 2008-10-03 2012-02-23 ザ・シャーロット‐メクレンバーグ・ホスピタル・オーソリティ，ドゥーイング・ビジネス・アズ・キャロライナズ・メディカル・センター Treatment of hepatitis C infection with metalloporphyrin
LT3210644T (en) 2009-05-27 2019-02-11 Ino Therapeutics Llc Devices for engaging indexed valve and pressurized canister assembly with collar
JP2011010865A (en) 2009-06-30 2011-01-20 Ikaria Holdings Inc Method of treating term and near-term neonate having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
US20120177601A1 (en) * 2009-07-02 2012-07-12 The Usa As Represented By The Secretary Of The Department Of Veterans Affairs Treatment of hepatitis c virus infections
ES2628634T3 (en) 2011-07-21 2017-08-03 Alfama, Inc. Carbon monoxide-ruthenium releasing molecules and uses thereof
WO2013022946A1 (en) 2011-08-09 2013-02-14 Beth Israel Deaconess Medical Center, Inc. Methods of treating dna damage
JP6457749B2 (en) * 2013-12-27 2019-01-23 ハウスウェルネスフーズ株式会社 VCAM-1 expression inhibitor
TW201618795A (en) 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
CN108057032B (en) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 Application of alweilin in preparation of medicine for preventing or treating portal hypertension
EP3524290A1 (en) * 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (en) * 1987-11-23 1989-05-24 Immuno Ag Fermenter for growing cell cultures
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
BR9405798A (en) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Methods for in vivo release of biological material and useful compositions thereof
WO1994022482A1 (en) 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (en) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermal therapeutic system for treatment of, e.g., hypertension
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (en) 1995-06-15 1997-07-25 Air Liquide CARBON MONOXIDE PRODUCTION PLANT INCORPORATING A CRYOGENIC SEPARATION UNIT
US5731326A (en) * 1995-06-30 1998-03-24 Zymogenetics, Inc. PDGF antagonists II
US5702325A (en) 1996-01-30 1997-12-30 Icon Health & Fitness, Inc. Cabinet treadmill with handle
ES2190467T3 (en) * 1996-02-27 2003-08-01 Koster Henk W BREATHING SYSTEM WITH AN ADDITIONAL GAS ADMINISTRATION MODULE.
JP2000510448A (en) * 1996-04-05 2000-08-15 ザ ジェネラル ホスピタル コーポレーション Treatment of hemoglobinopathies
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
PT921807E (en) 1996-08-27 2004-04-30 Messer Griesheim Gmbh MEDICINES CONTAINING HYDROGEN
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
DK0951292T3 (en) * 1996-09-27 2007-08-13 Univ Columbia Treatment of an ischemic disorder and improvement of stroke outcome
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
CN100390163C (en) 1998-03-16 2008-05-28 赛尔金有限公司 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (en) 2000-07-27 2003-01-03 Air Liquide Sante Int USE OF CO IN THE TREATMENT OF INFLAMMATION OF THE UPPER AIRWAYS OR BRONCHIA
FR2812545B1 (en) * 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
FR2816212A1 (en) 2000-11-03 2002-05-10 Air Liquide Sante Int Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US20030068387A1 (en) * 2001-03-30 2003-04-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7122027B2 (en) * 2001-05-25 2006-10-17 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
SK15942003A3 (en) * 2001-06-21 2004-08-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants apoptosis
US7174178B2 (en) 2001-07-19 2007-02-06 Intel Corporation Deriving a more accurate estimate from prediction data in closed loop transmit diversity modes
EP2042181A1 (en) * 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
JP2005525848A (en) * 2002-02-13 2005-09-02 ベス イスラエル ディコネス メディカル センター Treatment method of vascular disease
AU2003223562B2 (en) 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
AU2003216368B2 (en) 2002-04-15 2007-08-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
US8097585B2 (en) * 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
JP2005532314A (en) * 2002-05-09 2005-10-27 イエール ユニバーシティ Carbon monoxide as a biomarker and therapeutic agent
US20040052866A1 (en) 2002-05-17 2004-03-18 Otterbein Leo E. Methods of treating hepatitis
CA2487413A1 (en) * 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
PL375161A1 (en) 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
DE10230165A1 (en) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Method and device for the administration of carbon monoxide
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Also Published As

Publication number Publication date
EA200401525A1 (en) 2006-06-30
ATE521357T1 (en) 2011-09-15
CA2485465A1 (en) 2003-11-27
MXPA04011426A (en) 2005-10-19
EP1505990B1 (en) 2011-08-24
JP2005533021A (en) 2005-11-04
US9522163B2 (en) 2016-12-20
EP1505990A4 (en) 2008-02-20
ES2372273T3 (en) 2012-01-17
EP1505990A2 (en) 2005-02-16
US20130202720A1 (en) 2013-08-08
DK1505990T3 (en) 2011-11-21
PL205066B1 (en) 2010-03-31
CN1668314A (en) 2005-09-14
HRP20041071A2 (en) 2005-06-30
RS99304A (en) 2007-04-10
PL374177A1 (en) 2005-10-03
US20040052866A1 (en) 2004-03-18
US20140141103A1 (en) 2014-05-22
AU2003234585A1 (en) 2003-12-02
CN1668314B (en) 2011-01-12
WO2003096977A2 (en) 2003-11-27
JP4549847B2 (en) 2010-09-22
NO20045056L (en) 2005-02-16
UA83465C2 (en) 2008-07-25
US20120276220A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2003096977A3 (en) Methods of treating hepatitis
WO2003088923A3 (en) Methods of treating ileus
WO2004043341A3 (en) Treatment for hemorrhagic shock
RS91104A (en) Methods of treating necrotizing enterocolitis
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
ZA200305860B (en) Composition for heart disease, method to prepare same and uses thereof.
YU20050003A (en) Method and apparatus for the administration of co
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2003103585A3 (en) Methods of treating angiogenesis, tumor growth, and metastasis
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
WO2006000547A3 (en) Method for producing an iron sulfate-based phosphate adsorbent
MXPA03005340A (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides.
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (en) Method for preventing and treating diabetes using neurturin
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
TW200510437A (en) Phosphinane compound with immunomodulating activity
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof
WO2005047278A3 (en) Substituted dihydroquinazolines ii
MXPA05005915A (en) Therapeutic human albumin solutions with low prekallicrein activator (pka) activity and process for obtaining them.
WO2004037278A3 (en) Delocalization molecules and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-993/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2485465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003234585

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20041071A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2003728926

Country of ref document: EP

Ref document number: 374177

Country of ref document: PL

Ref document number: PA/a/2004/011426

Country of ref document: MX

Ref document number: 2004504976

Country of ref document: JP

Ref document number: 3596/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200401525

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038163233

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003728926

Country of ref document: EP